Solo founder claims two AI-designed drugs, now fundraising for pharma startup
LeoTZ03 · x · 2026-09-10
Douglas Yao is fundraising to build a pharma company where a single human operator runs the entire drug discovery process with AI and robotics. As proof, he developed PAC-832, billed as the world's first selective GalR1 antagonist for Alzheimer's, and PAC-3310, a selective M4 agonist for schizophrenia, alone with frontier AI models and liquid-handling robots, zero outside investment.
More from AGI Musings
- Ex-OpenAI/Anthropic researcher quits over 'reckless' superintelligence race, dissenters invoke Y2K — geoffwolfe · 2026-09-10
- Stanford Social Innovation Review: Relational Intelligence Matters More Than AI — round · 2026-09-10
- AI safety discourse is replaying 2020's pandemic expert free-for-all — SanhEstPasMoi · 2026-09-10
- Train on Frontier Papers or Build RL Envs? An Insider Debate on Math Model Training — ctjlewis · 2026-09-10
- AI extinction drama: researchers believe in the risk yet keep racing, says viral thread — AIandDesign · 2026-09-10
- François Fleuret asks: what intellectual endeavor can humanity still claim from AI in two years? — francoisfleuret · 2026-09-10